Improvement of Refractory Restless Legs Syndrome in a Parkinson’s Disease Patient After Semaglutide Treatment: A Novel Clinical Observation Authors: Pasquale Maria Pecoraro, Silvia Lodico, Francesco Bugamelli, Martina Di Carluccio, Lazzaro di Biase Published: 2026 Dear Editor, Restless legs syndrome (RLS) is a sensory–motor disorder marked by an urge to move the legs, typically worse at rest and in the evening, and is frequently comorbid with Parkinson’s disease (PD), and its prevalence in patients with PD exceeds that in the general population [1]. Standard therapies include dopaminergic agents and α2δ ligands (gabapentin/pregabalin), but contraindications, suboptimal response, or augmentation can limit their use [2,3]. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs), such as exenatide and semaglutide, have been shown to have potential neuroprotective, anti-inflammatory, and mitochondrial effects in experimental PD and early clinical studies [4,5]; however, the effects of these drugs on RLS have not been described. We herein report an observation suggesting a possible causal association between semaglutide exposure and changes in refractory RLS symptoms in a patient with PD. A 65-year-old man with a 7-year PD history (Hoehn & Yahr stage 2) presented with daily, evening-predominant RLS fulfilling the International RLS Study Group (IRLSSG) criteria [3]. which was partially relieved by movement; the baseline International Restless Legs Syndrome Study Group rating scale (IRLS) was 40. Motor symptoms were well controlled on levodopa (Movement Disorder Society–Unified Parkinson’s Disease Rating Scale Part III in the ON state: 16). Gabapentin was titrated up to 300 mg/day, but owing to mild confusion and somnolence, the patient maintained 200 mg/day for approximately 2.5 years with poor efficacy and eventually discontinued it without subsequent worsening. Pregabalin titrated up to 100 mg/day was also stopped for similar tolerability issues and lack of benefit; dopamine agonists were avoided because of a previous impulse-control disorder (hypersexuality) with a high dopaminergic load, after which the dose of levodopa was reduced. Comorbidities included hypertension, chronic kidney disease (CKD), obstructive sleep apnea diagnosed with polysomnography and treated with continuous positive airway pressure (CPAP), lumbar radiculopathies and peripheral neuropathies, and a history of heavy smoking. He had no history of diabetes mellitus. HbA1c was within the nondiabetic range (5.5%, 37 mmol/mol), with mildly elevated fasting glucose (121 mg/dL) and no urinary glucose. He reported constipation, intermediate insomnia, nocturnal jerks, and occasional bruxism. Neurologic examination showed mild hypomimia, bilateral postural tremor and rigidity, mild bradykinesia, mildly reduced arm swing, and preserved gait with some dyskinesias with left foot dystonic posturing. Routine blood tests revealed only a mildly elevated blood urea nitrogen level (60 mg/dL), in line with a previous history of CKD. An iron deficiency panel, which included blood iron, ferritin, transferrin and total iron binding capacity, was normal. Brain MRI revealed mild microangiopathic gliosis, whereas a 24-hour electroencephalogram study demonstrated sporadic bilateral frontocentral slow anomalies and two leg-movement events without EEG correlate. On somatosensory evoked potentials (SEPs), delayed/absent central conduction components, indicating the involvement of central somatosensory pathways, were found. Right common peroneal mononeuropathy and chronic lumbosacral radiculopathy were confirmed in a nerve conduction study. He was on levodopa/benserazide immediate release 200/50 mg fractionated (0.5 tab at 05:00 am and 1:00 pm; 0.25 tab at 09:00 am and 5:00 pm), carbidopa/levodopa continuous release 200/50 mg at bedtime, irbesartan 150 mg every morning, duloxetine 30 mg every morning, and febuxostat 80 mg at bedtime. In April 2024, he started subcutaneous semaglutide for metabolic/weight indications (0.25 mg weekly×4 weeks then 0.5 mg weekly). RLS severity was longitudinally monitored using the IRLS and a patient-reported monthly episode count. Approximately 3 weeks later, he reported marked RLS improvement—from daily episodes to a single mild episode per month—with the IRLS decreasing to 5, with the benefit persisting for more than 6 months. During this period, he lost approximately 10 kg and perceived his overall motor performance as stable or improved, and no neuropsychiatric or metabolic adverse events emerged. HbA1c remained within the nondiabetic range and decreased to 5.1% (32 mmol/mol), while glucose was 111 mg/dL. No changes in the dopaminergic regimen, antidepressant therapy, or CPAP settings occurred during the weeks preceding symptom improvement. The longitudinal trends in RLS severity before and after semaglutide initiation are shown in Figure 1. Longitudinal RLS severity before and after semaglutide initiation in a patient with PD. The blue curve shows the IRLS total score, and the orange curve shows the patient-reported number of RLS episodes per month. Month 0 indicates semaglutide initiation. IRLS, International Restless Legs Syndrome Study Group rating scale; RLS, restless legs syndrome PD, Parkinson’s disease. To our knowledge, this is the first clinical observation of semaglutide-associated improvement in RLS. The close temporal relationship (onset around 3 weeks), sustained response, and absence of concurrent medication changes support a potential mechanistic link, although causality cannot be established in a single case. GLP-1 RAs cross the blood–brain barrier and modulate microglial activation, mitochondrial function, and synaptic signaling; in PD models, GLP-1 signaling influences dopaminergic neurotransmission and neuroinflammation [6]. RLS pathophysiology involves subcortical dopaminergic dysfunction and abnormal iron handling within sensorimotor circuits [7]. Conceivably, GLP-1–mediated central actions could enhance striatal dopaminergic tone or improve sensory integration, lowering the drive for periodic leg movements and the urge to move the legs. The patient experienced substantial weight loss (approximately 10 kg over 3 months), which may have attenuated sleep fragmentation, indirectly alleviating RLS severity. However, the patient experienced weight loss over months, while the improvement in RLS occurred within 3 weeks after semaglutide initiation, supporting an early drug-driven effect. Peripheral contributors (peroneal mononeuropathy; lumbar radiculopathies) and central somatosensory pathway abnormalities (delayed/absent SEP components) might exacerbate leg dysesthesias, but rapid semaglutide-related improvement without pharmacological interventions targeting peripheral neuropathy suggests a possible centrally mediated effect. Indeed, his burning dysesthesias in a stocking distribution persisted during semaglutide treatment, while the urge to move the legs at rest improved, supporting their clinical distinction. However, polysomnography and actigraphy were not available, limiting the quantification of sleep continuity. The only available sleep-related information was the patient’s self-reported improvement in daytime sleepiness and concentration and his decision to discontinue CPAP 4 months after semaglutide initiation, as he no longer perceived it as necessary. Future work should prioritize objective sleep metrics and longitudinal assessments to better delineate the underlying mechanisms. In RLS with PD, the use of dopamine agonists can be limited by augmentation or psychiatric/impulse-control risks—as in our patient—while α2δ ligands may be ineffective or poorly tolerated. GLP-1 RAs, when indicated for metabolic reasons, might offer an ancillary benefit for patients with RLS with a favorable neuropsychiatric profile in selected patients, although controlled trials are essential. GLP-1 signaling may influence dopaminergic neurotransmission, potentially shifting the balance of subcortical sensorimotor processing implicated in RLS. A pilot study could explore the efficacy of semaglutide in RLS patients who are resistant to standard care. To conclude, semaglutide treatment resulted in a remarkable and sustained improvement in previously refractory RLS symptoms. This case suggests a potential novel therapeutic effect of GLP-1 RAs on RLS and supports further research into their neuromodulatory properties in sleep and sensory–motor disorders. Footnotes Ethics Statement Institutional Review Board approval was not required for this work. Written informed consent was obtained directly from the patient for participation in this work and for publication of the clinical details. In the form, the patient has given consent for his clinical information to be reported in the journal. The patient understands that names and initials will not be published and that due efforts will be made to conceal identity, but anonymity cannot be guaranteed. We confirm that we have read the Journal’s position on issues involved in ethical publication and affirm that this work is consistent with those guidelines. All study procedures were performed in accordance with the ethical standards of the 1964 Declaration of Helsinki and its later amendments. Conflicts of Interest The authors have no financial conflicts of interest. Funding Statement None Acknowledgments We thank the patient for his participation in the study. Author Contributions Conceptualization: Lazzaro di Biase. Data curation: Lazzaro di Biase, Pasquale Maria Pecoraro, Martina Di Carluccio, Silvia Lodico. Investigation: all authors. Project administration: Lazzaro di Biase. Supervision: Lazzaro di Biase. Validation: Lazzaro di Biase. Visualization: Lazzaro di Biase, Pasquale Maria Pecoraro. Writing—original draft: Pasquale Maria Pecoraro, Silvia Lodico, Martina Di Carluccio, Francesco Bugamelli. Writing—review & editing: Lazzaro di Biase. REFERENCES